Abeer H A Mohamed Ahmed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Abeer H A Mohamed Ahmed has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Steve Brocchini
UCL School of Pharmacy
5 shared publications Simon L. Croft
London School of Hygiene & Tropical Medicine
4 shared publicationsCatherine Tuleu
Department of Pharmaceutics, University College London, School of Pharmacy, United Kingdom
3 shared publicationsAlastair Lockwood
National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, UCL Institute of Ophthalmology, London, EC1V 2PD, UK
2 shared publicationsJessica Soto
Department of Pharmaceutics, University College London, School of Pharmacy, United Kingdom
2 shared publicationsKarin Seifert
Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom
2 shared publications
Latest Publications
- 1 August 2018
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 157, 100-106
LC–MS analysis to determine the biodistribution of a polymer coated ilomastat ocular implant
- 1 August 2018
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 157, 100-106
LC–MS analysis to determine the biodistribution of a polymer coated ilomastat ocular implant
- 1 January 2018
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 535 (1-2) , 194-200
Taste evaluation of a novel midazolam tablet for pediatric patients: In vitro drug dissolution, in vivo animal taste aversion and clinical taste perception profiles
- 1 January 2018
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 535 (1-2) , 194-200
Taste evaluation of a novel midazolam tablet for pediatric patients: In vitro drug dissolution, in vivo animal taste aversion and clinical taste perception profiles
- Top Cited Papers
- 10 October 2017
- Published by Wiley in British Journal of Pharmacology
- Vol. 174 (23) , 4205-4223
Principles of pharmacology in the eye
The eye is a highly specialized organ that is subject to a huge range of pathology. Both local and systemic disease may affect different anatomical regions of the eye. The least invasive routes for ocular drug administration are topical (e.g. eye drops) and systemic (e.g. tablets) formulations. Barriers that subserve as protection against pathogen entry also restrict drug permeation. Topically administered drugs often display limited bioavailability due to many physical and biochemical barriers including the pre‐corneal tear film, the structure and biophysiological properties of the cornea, the limited volume that can be accommodated by the cul‐de‐sac, the lacrimal drainage system and reflex tearing. The tissue layers of the cornea and conjunctiva are further key factors that act to restrict drug delivery. Using carriers that enhance viscosity or bind to the ocular surface increases bioavailability. Matching the pH and polarity of drug molecules to the tissue layers allows greater penetration. Drug delivery to the posterior segment is a greater challenge and, currently, the standard route is via intravitreal injection, notwithstanding the risks of endophthalmitis and retinal detachment with frequent injections. Intraocular implants that allow sustained drug release are at different stages of development. Novel exciting therapeutic approaches include methods for promoting transscleral delivery, sustained release devices, nanotechnology and gene therapy.
- 10 October 2017
- Published by Wiley in British Journal of Pharmacology
- Vol. 174 (23) , 4205-4223
Top Cited PapersPrinciples of pharmacology in the eye
The eye is a highly specialized organ that is subject to a huge range of pathology. Both local and systemic disease may affect different anatomical regions of the eye. The least invasive routes for ocular drug administration are topical (e.g. eye drops) and systemic (e.g. tablets) formulations. Barriers that subserve as protection against pathogen entry also restrict drug permeation. Topically administered drugs often display limited bioavailability due to many physical and biochemical barriers including the pre‐corneal tear film, the structure and biophysiological properties of the cornea, the limited volume that can be accommodated by the cul‐de‐sac, the lacrimal drainage system and reflex tearing. The tissue layers of the cornea and conjunctiva are further key factors that act to restrict drug delivery. Using carriers that enhance viscosity or bind to the ocular surface increases bioavailability. Matching the pH and polarity of drug molecules to the tissue layers allows greater penetration. Drug delivery to the posterior segment is a greater challenge and, currently, the standard route is via intravitreal injection, notwithstanding the risks of endophthalmitis and retinal detachment with frequent injections. Intraocular implants that allow sustained drug release are at different stages of development. Novel exciting therapeutic approaches include methods for promoting transscleral delivery, sustained release devices, nanotechnology and gene therapy.
- 1 August 2017
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 529 (1-2) , 310-318
Comparative in vitro and in vivo taste assessment of liquid praziquantel formulations
- 1 August 2017
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 529 (1-2) , 310-318
Comparative in vitro and in vivo taste assessment of liquid praziquantel formulations
- Open Access
- 1 July 2017
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 58 (9) , 3425-3431
An Ilomastat-CD Eye Drop Formulation to Treat Ocular Scarring
Purpose: The purpose of this study was to develop a topical matrix metalloproteinase inhibitor preparation for antiscarring therapy. Methods: The broad spectrum matrix metalloproteinase inhibitor ilomastat was formulated using 2-hydroxypropyl-β-cyclodextrin in aqueous solution. In vitro activity of ilomastat-cyclodextrin (ilomastat-CD) was examined using fibroblasts seeded in collagen. Permeation of ilomastat-CD eye drop through pig eye conjunctiva was confirmed using Franz diffusion cells. Ilomastat-CD eye drop was applied to rabbit eyes in vivo, and the distribution of ilomastat in ocular tissues and fluids was determined by liquid chromatography-mass spectroscopy. Results: The aqueous solubility of ilomastat-CD was ∼1000 μg/mL in water and 1400 μg/mL in PBS (pH 7.4), which is greater than ilomastat alone (140 and 160 μg/mL in water and PBS, respectively). The in vitro activity of ilomastat-CD to inhibit collagen contraction in the presence of human Tenon fibroblast cells was unchanged compared to uncomplexed ilomastat. Topically administered ilomastat-CD in vivo to rabbit eyes resulted in a therapeutic concentration of ilomastat being present in the sclera and conjunctiva and within the aqueous humor. Conclusions: Ilomastat-CD has the potential to be formulated as an eye drop for use as an antifibrotic, which may have implications for the prevention of scarring in many settings, for example glaucoma filtration surgery.
- 1 July 2017
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 58 (9) , 3425-3431
Open AccessAn Ilomastat-CD Eye Drop Formulation to Treat Ocular Scarring
Purpose: The purpose of this study was to develop a topical matrix metalloproteinase inhibitor preparation for antiscarring therapy. Methods: The broad spectrum matrix metalloproteinase inhibitor ilomastat was formulated using 2-hydroxypropyl-β-cyclodextrin in aqueous solution. In vitro activity of ilomastat-cyclodextrin (ilomastat-CD) was examined using fibroblasts seeded in collagen. Permeation of ilomastat-CD eye drop through pig eye conjunctiva was confirmed using Franz diffusion cells. Ilomastat-CD eye drop was applied to rabbit eyes in vivo, and the distribution of ilomastat in ocular tissues and fluids was determined by liquid chromatography-mass spectroscopy. Results: The aqueous solubility of ilomastat-CD was ∼1000 μg/mL in water and 1400 μg/mL in PBS (pH 7.4), which is greater than ilomastat alone (140 and 160 μg/mL in water and PBS, respectively). The in vitro activity of ilomastat-CD to inhibit collagen contraction in the presence of human Tenon fibroblast cells was unchanged compared to uncomplexed ilomastat. Topically administered ilomastat-CD in vivo to rabbit eyes resulted in a therapeutic concentration of ilomastat being present in the sclera and conjunctiva and within the aqueous humor. Conclusions: Ilomastat-CD has the potential to be formulated as an eye drop for use as an antifibrotic, which may have implications for the prevention of scarring in many settings, for example glaucoma filtration surgery.
- 21 February 2017
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 69 (4) , 480-488
Quality and stability of extemporaneous pyridoxal phosphate preparations used in the treatment of paediatric epilepsy
Objectives To assess the pyridoxal 5′‐phosphate (PLP) content and stability of extemporaneous PLP liquids prepared from dietary supplements used for the treatment of vitamin B6‐dependent epilepsy. Methods Pyridoxal 5′‐phosphate liquids were prepared in accordance with the guidelines given to patients from marketed 50 mg PLP dietary capsules and tablets. The PLP content and its stability were evaluated under conditions resembling the clinical setting using reverse phase HPLC and mass spectrometry. Key findings Pyridoxal 5′‐phosphate content in most of the extemporaneously prepared liquids from dietary supplements was found to be different from the expected amount (~16–60 mg). Most of these PLP extemporaneous liquids were stable at room temperature (protected from light) after 24 h but unstable after 4 h when exposed to light. A key photodegradation product of PLP in water was confirmed as 4‐pyridoxic acid 5′‐phosphate (PAP). Conclusion Pyridoxal 5′‐phosphate tablets from Solgar® were found to be the most reliable product for the preparation of extemporaneous PLP liquids. This work highlighted the difference between the marketed PLP dietary supplements quality and the importance of proper storage of aqueous PLP. There is a need to develop pharmaceutical forms of PLP that ensure dose accuracy and avoid potentially unsafe impurities with the aim of enhancing safety and compliance.
- 21 February 2017
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 69 (4) , 480-488
Quality and stability of extemporaneous pyridoxal phosphate preparations used in the treatment of paediatric epilepsy
Objectives To assess the pyridoxal 5′‐phosphate (PLP) content and stability of extemporaneous PLP liquids prepared from dietary supplements used for the treatment of vitamin B6‐dependent epilepsy. Methods Pyridoxal 5′‐phosphate liquids were prepared in accordance with the guidelines given to patients from marketed 50 mg PLP dietary capsules and tablets. The PLP content and its stability were evaluated under conditions resembling the clinical setting using reverse phase HPLC and mass spectrometry. Key findings Pyridoxal 5′‐phosphate content in most of the extemporaneously prepared liquids from dietary supplements was found to be different from the expected amount (~16–60 mg). Most of these PLP extemporaneous liquids were stable at room temperature (protected from light) after 24 h but unstable after 4 h when exposed to light. A key photodegradation product of PLP in water was confirmed as 4‐pyridoxic acid 5′‐phosphate (PAP). Conclusion Pyridoxal 5′‐phosphate tablets from Solgar® were found to be the most reliable product for the preparation of extemporaneous PLP liquids. This work highlighted the difference between the marketed PLP dietary supplements quality and the importance of proper storage of aqueous PLP. There is a need to develop pharmaceutical forms of PLP that ensure dose accuracy and avoid potentially unsafe impurities with the aim of enhancing safety and compliance.
- Open Access
- 1 July 2016
- Published by Elsevier in Drug Discovery Today
- Vol. 21 (7) , 1170-1180
Non-human tools for the evaluation of bitter taste in the design and development of medicines: a systematic review
- 1 July 2016
- Published by Elsevier in Drug Discovery Today
- Vol. 21 (7) , 1170-1180
Open AccessNon-human tools for the evaluation of bitter taste in the design and development of medicines: a systematic review
- 8 October 2013
- Published by Royal Society of Chemistry (RSC) in Polymer Chemistry
- Vol. 5 (3) , 1037-1048
Poly(methacrylic acid) complexation of amphotericin B to treat neglected diseases
Amphotericin B (AmB) is used to treat a neglected disease called visceral leishmaniasis (VL). We hypothesised that direct non-covalent association of AmB with poly(methacrylic acid) (PMAA) would replicate many of the properties of liposomal AmB (AmB-L), which is more efficacious than micellar AmB (AmB-D). Water-soluble AmB–PMAA complexes with AmB loadings ranging from ∼20 to 45% were reproducibly prepared. The AmB in the PMAA complex displayed similar aggregation properties to the AmB within AmB-L. The AmB–PMAA complex displayed low heamolytic properties while maintaining in vitro activity against Leishmania donovani amastigotes with no macrophage toxicity observed at an IC50 of 0.043 (±0.003) μM. AmB–PMAA complexes were well tolerated in vivo at a total dose of 6 mg kg−1 and both the complex (2.2 mg kg−1 AmB) and AmB-L (2.5 mg kg−1 AmB) achieved greater than 90% parasite inhibition in vivo after a single dose against L. donovani in HU3 infected BALB/c mice.
- 8 October 2013
- Published by Royal Society of Chemistry (RSC) in Polymer Chemistry
- Vol. 5 (3) , 1037-1048
Poly(methacrylic acid) complexation of amphotericin B to treat neglected diseases
Amphotericin B (AmB) is used to treat a neglected disease called visceral leishmaniasis (VL). We hypothesised that direct non-covalent association of AmB with poly(methacrylic acid) (PMAA) would replicate many of the properties of liposomal AmB (AmB-L), which is more efficacious than micellar AmB (AmB-D). Water-soluble AmB–PMAA complexes with AmB loadings ranging from ∼20 to 45% were reproducibly prepared. The AmB in the PMAA complex displayed similar aggregation properties to the AmB within AmB-L. The AmB–PMAA complex displayed low heamolytic properties while maintaining in vitro activity against Leishmania donovani amastigotes with no macrophage toxicity observed at an IC50 of 0.043 (±0.003) μM. AmB–PMAA complexes were well tolerated in vivo at a total dose of 6 mg kg−1 and both the complex (2.2 mg kg−1 AmB) and AmB-L (2.5 mg kg−1 AmB) achieved greater than 90% parasite inhibition in vivo after a single dose against L. donovani in HU3 infected BALB/c mice.
- Open Access
- 1 October 2013
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 57 (10) , 4608-4614
Antileishmanial Activity, Uptake, and Biodistribution of an Amphotericin B and Poly(α-Glutamic Acid) Complex
A noncovalent, water-soluble complex of amphotericin B (AMB) and poly(α-glutamic acid) (PGA), with AMB loadings ranging from 25 to 55% (wt/wt) using PGA with a molecular weight range of 50,000 to 70,000, was prepared as a potential new treatment for visceral leishmaniasis (VL). The AMB-PGA complex was shown to be as active as Fungizone (AMB deoxycholate) against intracellular Leishmania donovani amastigotes in differentiated THP-1 cells. The in vitro uptake of the AMB-PGA complex by differentiated THP-1 cells was similar to that of Fungizone and higher than that of AmBisome (liposomal AMB). The AMB-PGA complex also displayed a dose-response profile similar to that of AmBisome in vivo in BALB/c mice against L. donovani , with 50% effective doses (ED 50 s) of 0.24 ± 0.03 mg/kg of body weight for the AMB-PGA complex and 0.24 ± 0.06 mg/kg for AmBisome. A biodistribution study with mice indicated that the AMB-PGA complex cleared more rapidly from plasma than AmBisome, with a comparable low level of distribution to the kidneys.
- 1 October 2013
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 57 (10) , 4608-4614
Open AccessAntileishmanial Activity, Uptake, and Biodistribution of an Amphotericin B and Poly(α-Glutamic Acid) Complex
A noncovalent, water-soluble complex of amphotericin B (AMB) and poly(α-glutamic acid) (PGA), with AMB loadings ranging from 25 to 55% (wt/wt) using PGA with a molecular weight range of 50,000 to 70,000, was prepared as a potential new treatment for visceral leishmaniasis (VL). The AMB-PGA complex was shown to be as active as Fungizone (AMB deoxycholate) against intracellular Leishmania donovani amastigotes in differentiated THP-1 cells. The in vitro uptake of the AMB-PGA complex by differentiated THP-1 cells was similar to that of Fungizone and higher than that of AmBisome (liposomal AMB). The AMB-PGA complex also displayed a dose-response profile similar to that of AmBisome in vivo in BALB/c mice against L. donovani , with 50% effective doses (ED 50 s) of 0.24 ± 0.03 mg/kg of body weight for the AMB-PGA complex and 0.24 ± 0.06 mg/kg for AmBisome. A biodistribution study with mice indicated that the AMB-PGA complex cleared more rapidly from plasma than AmBisome, with a comparable low level of distribution to the kidneys.